A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety of LY3361237 and any side
effects that might be associated with it when given to participants with systemic lupus
erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The
study will last up to 26 weeks and may include up to 17 visits to the study center.